Please assess the completion status of the following clinical trial:

Trial Title: Varenicline for Nicotine Dependence Among Those With HIV/AIDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. 18 years of age or older who self-report smoking at least 5 cigarettes (menthol and non-menthol) per day, on average.~2. Diagnosed with HIV infection and exhibiting viral load of \< 1000 copies/mL and CD4+ counts of \> 200 cells/mm3 within 6 months prior to enrollment.~3. Able to use varenicline safely, based on a medical evaluation including medical history and physical examination, and psychiatric evaluation.~4. Residing in the geographic area for at least 7 months.~5. Women of childbearing potential (based on medical history and physical exam) must consent to use a medically accepted method of birth control (e.g., condoms and spermicide, oral contraceptive, Depo-Provera injection, contraceptive patch, tubal ligation) or abstain from sexual intercourse during the time they are taking study medication and for at least one month after the medication period ends.~6. If current or past diagnosis of bipolar disorder (I, II, or NOS), eligible if:~   1. No psychotic features~  2. MADRS: total score \< 8 (past 4 weeks), suicidal item score \< 1 (past 4 weeks)~  3. Y-MRS: total score \< 8 (past 4 weeks), irritability, speech content, disruptive, or aggressive behavior items score \< 3 (past 4 weeks)~  4. No psychiatric hospitalization or Emergency Room visits for psychiatric issues in the past 6 months~  5. No aggressive or violent acts or behavior in the past 6 months~7. Able to communicate fluently in English.~8. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent/HIPAA form.~Exclusion Criteria:~Smoking Behavior~1. Current enrollment or plans to enroll in another smoking cessation program in the next 7 months.~2. Regular (daily) use of chewing tobacco, snuff, snus, cigars, cigarillos, or pipes.~3. Current use or plans to use nicotine substitutes (gum, patch, lozenge, e-cigarette) or smoking cessation treatments in the next 7 months.~   1. Note: Once participants are found eligible for the study, they are told they should refrain from using any nicotine replacement therapy (NRT) for the duration of the study. If a subject reports an isolated (non-daily) instance of NRT use during the study, they may be permitted to continue.~Alcohol/Drug Exclusion Criteria~1. Current untreated and unstable diagnosis of substance abuse or dependence (eligible if past use and if receiving treatment and stable for \>30 days).~2. Positive urine drug screen (for cocaine and/or methamphetamines) at the Intake Session.~3. Breath Alcohol Concentration (BrAC) assessment greater than or equal to 0.01 at the Intake Session.~Medication Exclusion Criteria~Current use or recent discontinuation (within last 14 days) of the following medications:~1. Other smoking cessation medications (e.g. Zyban, Wellbutrin, Wellbutrin SR, Chantix)~   a. Note: Once participants are found eligible for the study, they are instructed to only use the smoking cessation medication provided to them by the study staff. If a subject reports an isolated (non-daily) instance of using a non-study smoking cessation medication, the study physician and PI will evaluate the situation and determine if it is safe for the subject to continue participation.~2. Anti-psychotic medications.~Medical Exclusion Criteria~1. Women who are pregnant, planning a pregnancy within the next 7 months, or lactating.~2. Current diagnosis of unstable and untreated major depression, as determined by self-report \& MINI (eligible if stable for \>30 days).~3. Current or past diagnosis of psychotic disorder, as determined by self-report or MINI.~4. Any suicide risk score on MINI, current suicidal ideation on Columbia scale, or self-reported lifetime suicide attempt.~5. History of heart disease, stroke or MI, unstable angina, or tachycardia (if stable, requires Study Physician approval).~6. Uncontrolled hypertension (SBP \>160 or DBP \>100).~   a. Note: If a participant presents with blood pressure greater than 160/100 at sessions occurring on Week 0 (Pre-Quit) or at any other point during the treatment period, they will not be provided with/able to continue on medication unless the study physician grants approval.~7. History of kidney or liver failure.~8. Abnormal ECG (unless approved by study physician).~9. Estimated creatinine clearance \<50 mL/min, within 6 months prior to enrollment.~10. AST and/or ALT results greater than 2 times the upper limit of normal, within 6 months prior to enrollment.~11. Any impairment (physical, neurological, visual) preventing cognitive task performance.~12. Previous allergic reaction to varenicline.~General Exclusion Criteria~1. Any medical condition or concomitant medication that could compromise subject safety or treatment, as determined by the Principal Investigator and/or Study Physician.~2. Inability to provide informed consent or complete any of the study tasks as determined by the Principal Investigator and/or Study Physician.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Varenicline (Type: ACTIVE_COMPARATOR): 12 weeks of active varenicline + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
- Placebo (Type: PLACEBO_COMPARATOR): 12 weeks of placebo + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally

Based on this trial design, predict the completion outcome and termination type (if applicable).